Short answer: Yes - there are now two oral GLP-1s approved for weight loss (as of April 2026).
Oral Wegovy (semaglutide) is FDA-approved for weight loss. It was approved on December 22, 2025, and became available in early January 2026. It's the first oral GLP-1 actually approved for weight loss, not just diabetes.
The results are solid: in the OASIS 4 trial, people who stuck with it lost about 16.6% of their body weight at 64 weeks (about 13.6% on average when you count everyone who started). That's close to what you see with injectable Wegovy. The dose is 25mg once daily, and the introductory price is $149/month.
The downside: you still have to take it on an empty stomach and wait 30 minutes before eating or drinking anything. Same routine as Rybelsus. If you were hoping for a pill you could just pop with breakfast, this isn't quite it.
What about Rybelsus? It's still around, but it's only approved for diabetes, not weight loss. And now that oral Wegovy exists, there's really no reason to mess with Rybelsus for weight loss anymore.
What about oral tirzepatide (Mounjaro/Zepbound)? Eli Lilly is not developing an oral version of tirzepatide. Any company selling "oral" or "sublingual" tirzepatide is selling a compounded product that's not FDA-approved. Personally, I would avoid it.
Foundayo (orforglipron) — FDA approved April 1, 2026: Eli Lilly's Foundayo was approved on April 1, 2026, after receiving priority review. The ATTAIN-1 trial showed about 12.4% weight loss among completers (11.1% on an intent-to-treat basis) at the highest dose — roughly 25–27 lbs on average.
The appeal of Foundayo: you can take it any time, no empty stomach requirement, no waiting period. Take it with your morning coffee or with dinner. That's a real convenience advantage over oral Wegovy or Rybelsus.
On paper, the weight loss numbers are a bit lower than the injectable GLP-1s — but real-world compliance with a no-restrictions daily pill is likely to close that gap. And the ATTAIN-MAINTAIN trial showed it can help maintain weight loss after switching from injectables — people who switched from Wegovy maintained about 95% of their prior weight loss, and people who switched from Zepbound maintained about 80%. So one option is using a shot to lose the weight, then switching to Foundayo to maintain it without the needles.
On pricing: Foundayo starts at $149/month for self-pay at lower doses, up to $299/month at the highest dose through Lilly's Self-Pay Journey program ($349/month without it). If you have commercial insurance, Lilly's savings card brings it down to $25/month. Medicare Part D coverage kicks in at $50/month starting July 1, 2026. Prescriptions through LillyDirect started shipping April 6, 2026, with broad retail and telehealth availability expected shortly after.
What about Pfizer's danuglipron? They discontinued it in April 2025 due to liver toxicity concerns.
Bottom line: For most people, Foundayo is the better oral GLP-1 to start with. Yes, oral Wegovy produces slightly better weight loss in clinical trials — but trials measure what happens under ideal conditions. In the real world, a pill you can take with your morning coffee is a pill you'll actually take every day. The empty stomach + 30-minute wait that oral Wegovy requires is the kind of friction that kills compliance over months and years. Foundayo's convenience edge matters more than a few percentage points of trial efficacy if it means you stick with it. And at $25/month with insurance, the cost barrier is basically gone.
That said, oral Wegovy is still a solid option if you're already comfortable with the fasting routine (especially if you were on Rybelsus). And if you want the absolute best results regardless of how you take it? The injections are still king. But the pill options are finally here and actually worth considering.
Stay tuned, we'll keep this article updated as things develop!
Last updated April 1, 2026 following FDA approval of Foundayo (orforglipron).